When is the Darzalex (daratumumab) patent due to end?
Darzalex’s “due day” depends on which protection you mean—drug patents (covering the medicine itself), method-of-use patents (covering how it’s used), or exclusivity rules that can extend market protection even if a patent expires. The exact end date also varies by country.
What exactly does “patent due” usually refer to for drugs like Darzalex?
For cancer biologics, “due day” often gets used to mean one of these:
- The end of the last relevant patent covering daratumumab in a specific jurisdiction.
- The end of market exclusivity (regulatory protection) that can delay approval of competing products even after a patent expires.
- The date a biosimilar can be approved and/or launched (approval timing and launch timing can differ).
Where does Darzalex protection stand by market (US vs EU vs UK)?
Patent and exclusivity timelines differ across the US, EU, and UK because they use different patent filings and different regulatory exclusivity frameworks. To give a specific date, you need:
- The country (or region)
- The specific form (for example, Darzalex vs Darzalex Faspro)
- Whether you mean the last patent expiry date or the earliest biosimilar/competitive entry date
Can biosimilars enter before all patents expire?
Yes. Biosimilars can sometimes be approved to enter the market while certain patents still exist, but courts can restrict launches or require changes in labeling depending on how infringement disputes play out. That means “first legal entry” can be later than the first possible approval.
What information do you need from me to pinpoint the exact date?
Tell me:
1) Which country/region (US, EU, UK, etc.)
2) Which product name (Darzalex or Darzalex Faspro)
3) Whether you want “last patent expiry” or “earliest biosimilar entry”
With those three details, I can give the most relevant “due day” for that specific protection.